The National Cancer Institute (NCI) estimates that the aging US population will contribute to a substantial increase in the number of older cancer survivors over the next 25 years.
Baby boomers strike again...this time among cancer survivors. The National Cancer Institute (NCI) estimates that the aging US population will contribute to a substantial increase in the number of older cancer survivors over the next 25 years.
This could mean a substantial stress on the already stretched resources of the healthcare system. Cancer survivors have unique needs; add to that the comorbidities in the older age group and the result is a very complicated healthcare map.
For this predictive modeling study, researchers from the NCI’s Division of Cancer Control and Population Sciences (DCCPS) analyzed incidence and survival data from 1975 to 2011, gathered from the Surveillance, Epidemiology, and End Results (SEER) Program, while the comorbidity burden was estimated from the SEER-Medicare claims data. The DCCPS scientists discovered 15.5 million cancer survivors in 2016, less than 38% of whom were under 65. By 2040, it was estimated that this number would grow to 26.1 million, 73% of whom would be over 65. Only 18% of cancer survivors are predicted to be between 50 and 64 years of age, and just about 8% will be younger than 50. The scientists write that these trends foreshadow a ‘silver tsunami’ of cancer survivors whose health needs we are unprepared to meet.
According to the study’s senior author, Shirley Bluethmann, PhD, MPH, what sets the research apart is that the seniors in the study were further divided into age groups, instead of being clumped together as being 65 and older. “We know that the health and function of older adults is extremely diverse, and [we] thought it would be valuable to provide more discrete estimates of prevalence across the older population of survivors,” she said in an interview.
For instance, by the year 2040, the study predicts that a sizable portion of the older survivors will be over 85 years old. Additionally, 26% of survivors in their late 60s had severe comorbidities, compared with 47% of those 85 and older. The cancer site mattered as well—lung cancer survivors seemed to have the highest burden of comorbidities, the study found.
These results have a far-reaching impact on the current structure of the US healthcare system, and needs a new approach. “Training diverse providers—including nurses, nurse practitioners, and physician assistants—to help with cancer-specific follow-up may be important to assist in the growing burden of caring for older survivors,” Bluethmann said.
Reference
Bluethmann SM, Mariotto AB, Rowland JH. Anticipating the “silver tsunami”: prevalence trajectories and comorbidity burden among older cancer survivors in the United States Cancer Epidemiol Biomarkers Prev. 2016;25(7):1029-1036. doi:10.1158/1055-9965.EPI-16-0133.
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Many Patients With Psoriasis in Clinical Trials Experience Nocebo Effects, Study Finds
April 18th 2024Half of patients exposed to placebo in clinical trials experienced adverse events (AEs), which may be partially explainable by nocebo effects, according to a recent review and meta-analysis.
Read More